SCHEDULE: Balyasny Asset Management Reports 5.18% Stake in Neurogene Inc.

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 818,706 shares, representing 5.18% of Neurogene Inc.'s common stock as of June 30, 2026.

Summary

• Balyasny Asset Management L.P. (BAM), along with BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively known as the Reporting Persons, have filed a Schedule 13G.
• The filing indicates that the Reporting Persons beneficially own 818,706 shares of Neurogene Inc. common stock.
• This ownership stake represents 5.18% of the total outstanding shares.
• The reporting date for this ownership is June 30, 2026.
• The shares are held through Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of BAM.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting a change in beneficial ownership without indicating a significant shift in strategy or performance.

Positives

• Disclosure of a significant ownership stake (5.18%) by a notable asset manager, Balyasny Asset Management, which could signal confidence in Neurogene Inc.'s prospects.
• The reporting is conducted in accordance with regulatory requirements, ensuring transparency for investors.

Negatives

• The filing is purely informational regarding ownership and does not provide any insights into the company's operational performance, financial health, or future strategy.
• No specific details are provided regarding the investment thesis or the rationale behind acquiring this stake.

Risks

• Potential for increased market volatility in Neurogene Inc. stock due to the significant stake held by an active asset manager.
• The concentration of ownership could lead to future strategic shifts or influence corporate decisions, the impact of which is currently unknown.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Neurogene Inc. It solely reports on the ownership stake of Balyasny Asset Management.

Industry Context

StockSavvy.ai notes that significant stake disclosures by institutional investors like Balyasny Asset Management are common in the biotechnology and pharmaceutical sectors, often indicating a belief in the company's research and development pipeline or market potential.

Stakeholder Impact

• Shareholders may view the increased institutional ownership positively, potentially leading to greater market liquidity and investor interest.
• The company's management may face increased scrutiny or engagement from Balyasny Asset Management regarding corporate strategy and performance.

Next Steps

• Monitor future filings from Balyasny Asset Management for any changes in their stake in Neurogene Inc.
• Observe Neurogene Inc.'s strategic communications for any potential impact from this increased institutional interest.

Key Dates

Keywords

Neurogene Inc., Schedule 13G, Balyasny Asset Management, Beneficial Ownership, Common Stock, Investment Management, Institutional Investor